EUVIMEDEUVIMED entdecken
Open Access

Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production

Ryan Reyes, Nissar A Wani, Kalpana Ghoshal, Samson T Jacob, Tasneem Motiwala

Gene Expression · 10.02.2017 · 17 (2) · 129-140

DOI: 10.3727/105221616x693855 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gene Expression, erschienen am 10.02.2017. Verfasst von Ryan Reyes und 4 weiteren Autor:innen. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths globally. Sorafenib is the only first-line systemic drug for advanced HCC, but it has very limited survival benefits because patients treated with sorafenib either suffer from side effects or show disease progression after initial response. Thus, there is an urgent need to develop novel strategies for first-line and second-line therapies. The association between sorafenib resistance and glycolysis prompted us to screen several drugs with known antiglycolytic activity to identify those that will sensitize cells to sorafenib. We demonstrate that the combination of glycolytic inhibitor 2-deoxyglucose (2DG) and sorafenib drastically inhibits viability of sorafenib-sensitive and -resistant cells. However, the combination of other antiglycolytic drugs like lonidamine, gossypol, 3-bromopyruvate, and imatinib with sorafenib does not show synergistic effect. Cell cycle analysis revealed that the combination of 2DG and sorafenib induced cell cycle arrest at G 0 /G 1 . Mechanistic investigation suggests that the cell cycle arrest is due to depletion of cellular ATP that activates AMP-activated protein kinase (AMPK), which, in turn, inhibits mammalian target of rapamycin (mTOR) to induce cell cycle arrest. This study provides strong evidence for the therapeutic potential of the combination of sorafenib and 2DG for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AMP-Activated Protein KinasesAdenosine TriphosphateAntineoplastic Combined Chemotherapy ProtocolsApoptosisCarcinoma, HepatocellularCell Cycle CheckpointsCell Line, TumorCell ProliferationDeoxyglucoseDrug SynergismG1 PhaseHumansLiver NeoplasmsNiacinamidePhenylurea CompoundsResting Phase, Cell CycleSorafenib

Substanzen

Phenylurea CompoundsNiacinamideAdenosine TriphosphateDeoxyglucoseSorafenibAMP-Activated Protein Kinases

Förderung

  • NCI NIH HHS

Zitieren

APA

Reyes, R., Wani, N. A., Ghoshal, K., Jacob, S. T., & Motiwala, T. (2017). Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production. Gene Expression, 17(2), 129-140. https://doi.org/10.3727/105221616x693855

Vancouver

Reyes R, Wani NA, Ghoshal K, Jacob ST, Motiwala T. Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production. Gene Expression. 2017;17(2):129-140. doi:10.3727/105221616x693855

BibTeX
@article{Reyes2017,
  author = {Reyes, Ryan and Wani, Nissar A and Ghoshal, Kalpana and Jacob, Samson T and Motiwala, Tasneem},
  title = {Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production},
  journal = {Gene Expression},
  year = {2017},
  volume = {17},
  number = {2},
  pages = {129--140},
  doi = {10.3727/105221616x693855}
}
Kostenlos starten →